Hep C Trial Reports Good Results for Alisporivir
Share
Follow Us
November 14, 2011
Interferon-Free Alisporivir Treatment Showing Promise in Genotype 2/3 Trial
Alisporivir, a once-daily drug being developed by Novartis at the forefront of a new class of hepatitis C virus (HCV) compounds known as cyclophilin inhibitors, is showing promise as a component of interferon-free therapy for people with genotype 2 or 3 HCV infection, according to new results from a Phase II study reported in San Francisco at the 62nd annual meeting of the American Association for the Study of Liver Diseases.
Nearly half of all study volunteers using the drug in combination with ribavirin, but without interferon, have undetectable HCV levels after six weeks of treatment, reported Jean-Michel Pawlotsky, MD, of the University of East Paris and his colleagues. In addition, roughly a third of the genotype 2/3 patients in the study had undetectable HCV levels at the six-week mark of therapy with alisporivir alone–use of the drug without either pegylated interferon or ribavirin.
Continue reading this entire article:
http://www.aidsmeds.com/articles/alisporovir_interferon_hcv_1667_21445.shtml
